Bruker (BRKR) Current Deferred Revenue (2016 - 2026)
Bruker filings provide 16 years of Current Deferred Revenue readings, the most recent being $550.4 million for Q4 2025.
- On a quarterly basis, Current Deferred Revenue rose 2.27% to $550.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $550.4 million, a 2.27% increase, with the full-year FY2025 number at $550.4 million, up 2.27% from a year prior.
- Current Deferred Revenue hit $550.4 million in Q4 2025 for Bruker, up from $455.4 million in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $590.8 million in Q1 2024 to a low of $175.5 million in Q3 2022.
- Median Current Deferred Revenue over the past 5 years was $435.3 million (2021), compared with a mean of $423.3 million.
- Biggest five-year swings in Current Deferred Revenue: soared 176.98% in 2021 and later tumbled 56.19% in 2022.
- Bruker's Current Deferred Revenue stood at $197.5 million in 2021, then surged by 138.84% to $471.7 million in 2022, then fell by 15.2% to $400.0 million in 2023, then surged by 34.55% to $538.2 million in 2024, then grew by 2.27% to $550.4 million in 2025.
- The last three reported values for Current Deferred Revenue were $550.4 million (Q4 2025), $455.4 million (Q3 2025), and $478.1 million (Q2 2025) per Business Quant data.